# OKG Capital

> OKG Capital is a VC fund backing Health Care, Medical and Software. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 9
- Last investment: May 2026
- Lead investor: 11%
- Last updated: Aug 2026

OKG Capital is a VC fund focused on Health Care and Medical. OKG Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 56% |
| Medical | 3 | 33% |
| Software | 2 | 22% |
| Machine Learning | 2 | 22% |
| Biotechnology | 1 | 11% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 22% |
| Pre-Seed | 2 | 22% |
| Series A | 2 | 22% |
| Funding Round | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 3 | 33% |
| Germany | 2 | 22% |
| United States | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $3.9M | Seed | May 27, 2026 |  |
| aiomics | Aiomics \| Back to your calling.Across Europe, healthcare providers lose hours every day to fragmented documentation—handwritten notes, scanned PDFs, dictations, disconnected IT systems. The result: burnout, missed revenue, and patients feeling like they’re asked the same question three times.Aiomics changes this. Our AI-driven co-pilot capturesevery clinical detail—speech, handwriting, digital notes—and validates it in real time with a human-in-the-loop process. Interactive checklists surface missing information before the patient leaves, and audit-ready records flow straight back into existing systems. Built for GDPR, MDR, and the EU AI Act from day one, Aiomics makes documentation complete, compliant, and instantly usable.We don’t replace EHRs—we make them better. From admission and discharge reports to insurer forms, from therapist briefings to patient-friendly letters, Aiomics turns paperwork from a burden into an asset. For providers, that means fewer errors, faster reimbursements, and—most importantly—more time at the bedside.Our mission: to empower healthcare professionals by removing administrative burdens and elevating their decision-making with trusted AI guidance—so they can reconnect with why they chose this vocation in the first place.Who we are: Aiomics is co-founded by Dr. Sven Jungmann, a physician with frontline experience of administrative overload; Dr. Nikita Tarasov, a physicist and data scientist; and a lawyer who scaled one of Europe’s largest digital service companies. Together, we unite empathy, technical mastery, and regulatory expertise to build the trusted co-pilot for Europe’s healthcare providers. |  | Pre-Seed | Apr 19, 2025 |  |
| 52 North Health | 52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $6M |  | Dec 03, 2024 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M | Seed | Nov 04, 2024 |  |
| DeepLook Medical | DeepLook Medical is a medical software. They use shape-recognition software to extract and assemble that data, revealing radiomic features that uniquely reflect tissue morphology. The phenotype database for mammography is a database of breast cancer morphology offered today for research purposes only. |  | Series A | Sep 18, 2024 |  |
| DeepLook Medical | DeepLook Medical is a medical software. They use shape-recognition software to extract and assemble that data, revealing radiomic features that uniquely reflect tissue morphology. The phenotype database for mammography is a database of breast cancer morphology offered today for research purposes only. | $1.7M | Seed | Feb 08, 2024 |  |
| iQure Pharma | iQure Pharma is a global biotech company created by entrepreneurs and former pharma managers that focuses on the development of new therapeutics. | $1.2M | Venture - Series Unknown | Oct 11, 2023 |  |
| Halitus | Laser Technology x Gas Dynamics Analysis x Machine Learning. | $1.1M | Pre-Seed | Jul 05, 2023 |  |
| OxCan | OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $11M | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [Meridian Health Ventures](https://shizune.co/investors/profile/khp-ventures) — VC Fund, 4 deals together
- [QantX](https://shizune.co/investors/profile/qantx) — VC Fund, 3 deals together
- [Infinite Digital](https://shizune.co/investors/profile/infinite-digital-9876) — VC Fund, 2 deals together
- [Macmillan Cancer Support](https://shizune.co/investors/profile/macmillan-cancer-support) — VC Fund, 2 deals together
- [Raw Ventures](https://shizune.co/investors/profile/raw-ventures) — VC Fund, 2 deals together
- [We Venture Capital](https://shizune.co/investors/profile/we-venture-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does OKG Capital invest in?

OKG Capital invests primarily in Health Care, Medical and Software startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did OKG Capital last invest?

The most recent investment recorded for OKG Capital closed in May 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co